Acute kidney injury in critical COVID-19: a multicenter cohort analysis in seven large hospitals in Belgium.
Acute kidney injury
COVID-19
Epidemiology
Intensive care unit
KDIGO
Kidney replacement therapy
Mortality
Renal replacement therapy
Serum creatinine
Urine output
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
25 07 2022
25 07 2022
Historique:
received:
07
04
2022
accepted:
02
07
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Acute kidney injury (AKI) has been reported as a frequent complication of critical COVID-19. We aimed to evaluate the occurrence of AKI and use of kidney replacement therapy (KRT) in critical COVID-19, to assess patient and kidney outcomes and risk factors for AKI and differences in outcome when the diagnosis of AKI is based on urine output (UO) or on serum creatinine (sCr). Multicenter, retrospective cohort analysis of patients with critical COVID-19 in seven large hospitals in Belgium. AKI was defined according to KDIGO within 21 days after ICU admission. Multivariable logistic regression analysis was used to explore the risk factors for developing AKI and to assess the association between AKI and ICU mortality. Of 1286 patients, 85.1% had AKI, and KRT was used in 9.8%. Older age, obesity, a higher APACHE II score and use of mechanical ventilation at day 1 of ICU stay were associated with an increased risk for AKI. After multivariable adjustment, all AKI stages were associated with ICU mortality. AKI was based on sCr in 40.1% and UO in 81.5% of patients. All AKI stages based on sCr and AKI stage 3 based on UO were associated with ICU mortality. Persistent AKI was present in 88.6% and acute kidney disease (AKD) in 87.6%. Rapid reversal of AKI yielded a better prognosis compared to persistent AKI and AKD. Kidney recovery was observed in 47.4% of surviving AKI patients. Over 80% of critically ill COVID-19 patients had AKI. This was driven by the high occurrence rate of AKI defined by UO criteria. All AKI stages were associated with mortality (NCT04997915).
Sections du résumé
BACKGROUND
Acute kidney injury (AKI) has been reported as a frequent complication of critical COVID-19. We aimed to evaluate the occurrence of AKI and use of kidney replacement therapy (KRT) in critical COVID-19, to assess patient and kidney outcomes and risk factors for AKI and differences in outcome when the diagnosis of AKI is based on urine output (UO) or on serum creatinine (sCr).
METHODS
Multicenter, retrospective cohort analysis of patients with critical COVID-19 in seven large hospitals in Belgium. AKI was defined according to KDIGO within 21 days after ICU admission. Multivariable logistic regression analysis was used to explore the risk factors for developing AKI and to assess the association between AKI and ICU mortality.
RESULTS
Of 1286 patients, 85.1% had AKI, and KRT was used in 9.8%. Older age, obesity, a higher APACHE II score and use of mechanical ventilation at day 1 of ICU stay were associated with an increased risk for AKI. After multivariable adjustment, all AKI stages were associated with ICU mortality. AKI was based on sCr in 40.1% and UO in 81.5% of patients. All AKI stages based on sCr and AKI stage 3 based on UO were associated with ICU mortality. Persistent AKI was present in 88.6% and acute kidney disease (AKD) in 87.6%. Rapid reversal of AKI yielded a better prognosis compared to persistent AKI and AKD. Kidney recovery was observed in 47.4% of surviving AKI patients.
CONCLUSIONS
Over 80% of critically ill COVID-19 patients had AKI. This was driven by the high occurrence rate of AKI defined by UO criteria. All AKI stages were associated with mortality (NCT04997915).
Identifiants
pubmed: 35879765
doi: 10.1186/s13054-022-04086-x
pii: 10.1186/s13054-022-04086-x
pmc: PMC9310674
doi:
Banques de données
ClinicalTrials.gov
['NCT04997915']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
225Informations de copyright
© 2022. The Author(s).
Références
J Trauma Acute Care Surg. 2021 May 1;90(5):880-890
pubmed: 33891572
Kidney Int. 2021 Sep;100(3):516-526
pubmed: 34252450
Contrib Nephrol. 2013;182:5-12
pubmed: 23689652
BMC Infect Dis. 2022 Mar 2;22(1):207
pubmed: 35236299
Intensive Care Med. 2013 Mar;39(3):420-8
pubmed: 23291734
Blood Purif. 2021;50(4-5):499-505
pubmed: 33291098
Nat Rev Nephrol. 2017 Apr;13(4):241-257
pubmed: 28239173
Ann Intensive Care. 2021 May 31;11(1):86
pubmed: 34057648
Am J Respir Crit Care Med. 2017 Mar 15;195(6):784-791
pubmed: 27635668
Intensive Care Med. 2021 Aug;47(8):819-834
pubmed: 34160631
J Am Soc Nephrol. 2015 Sep;26(9):2231-8
pubmed: 25568178
Ther Apher Dial. 2022 Jan 6;:
pubmed: 34990070
J Intensive Care Med. 2020 Oct;35(10):963-970
pubmed: 32812834
Lancet. 2021 Apr 3;397(10281):1293-1300
pubmed: 33812488
Ann Surg. 2020 Oct;272(4):e280-e281
pubmed: 32932328
Crit Care. 2016 Sep 27;20(1):299
pubmed: 27670788
Ann Intensive Care. 2021 Aug 6;11(1):123
pubmed: 34357478
J Intensive Care Med. 2021 Mar;36(3):319-326
pubmed: 33267722
Clin Kidney J. 2021 Jan 24;14(Suppl 1):i30-i39
pubmed: 33796284
Crit Care. 2020 May 14;24(1):219
pubmed: 32410714
Acta Clin Belg. 2021 Oct 28;:1-8
pubmed: 34709997
Crit Care. 2021 Mar 25;25(1):121
pubmed: 33766109
Nat Rev Nephrol. 2021 Nov;17(11):751-764
pubmed: 34226718
Nat Rev Nephrol. 2020 Dec;16(12):747-764
pubmed: 33060844
J Am Soc Nephrol. 2021 Jan;32(1):151-160
pubmed: 32883700
Intensive Care Med. 2015 Aug;41(8):1411-23
pubmed: 26162677
Crit Care. 2013 Jun 20;17(3):R112
pubmed: 23787055
Kidney Int. 2011 Oct;80(7):760-7
pubmed: 21716258
N Engl J Med. 2018 Oct 11;379(15):1431-1442
pubmed: 30304656
N Engl J Med. 2020 Jul 16;383(3):240-251
pubmed: 32668114
Crit Care Med. 2021 Aug 1;49(8):e781-e792
pubmed: 33861550
Kidney Int. 2020 Nov;98(5):1296-1307
pubmed: 32791255
Crit Care. 2006;10(3):R73
pubmed: 16696865
Clin J Am Soc Nephrol. 2022 Mar;17(3):342-349
pubmed: 35210281